ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: FR-PO100

Statins and Contrast Induced-AKI: A Systematic Review and Meta-Analysis

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology‚ Risk Factors‚ and Prevention


  • Chittoor, Shriman, Fort Bend Independent School District, Sugar Land, Texas, United States
  • Kohli, Kripa, Fort Bend Independent School District, Sugar Land, Texas, United States
  • Navaneethan, Sankar D., Baylor College of Medicine, Houston, Texas, United States

Several treatment options are available to reduce the incidence of contrast-induced acute kidney injury (CI-AKI). Clinical trial evidence reported conflicting data on the incidence of CIN with statins. Hence, we conducted a systematic review and meta-analysis to evaluate the effects of statins as well as compare the effects of different doses of statins on the incidence of CI-AKI.


We searched MEDLINE and other databases (until March 2022) for randomized control trials (RCTs) that compared the effect of statin treatment on the incidence of CI-AKI or trials that compared high-dose vs. low-dose statin treatments on the occurrence of CI-AKI. Two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random-effects model and results were expressed as a risk ratio (RR) for dichotomous outcomes with 95% confidence intervals (CI). Quality assessment was conducted using Cochrane quality assessment method.


Seven RCTs (6635 patients) comparing statins to placebo and 2 trials (1204 patients) comparing low dose to high dose statins were included. There was a 59% reduction in the incidence of CIN with statins (7 trials, 6655 patients, Pooled RR- 0.59, 95% CI 0.44- 0.79) compared to placebo with no significant heterogeneity between the included studies [Figure]. However, there was no impact on the incidence of CI-AKI warranting dialysis with statins (Pooled RR- 0.28, 95% CI 0.05-1.70). High dose statins (vs. low dose statins) did not lower the incidence of CI-AKI (Pooled RR- 0.70, 95% CI 0.39-1.26) and CI-AKI warranting dialysis. Most included studies had mild-moderate risk of bias.


Statins use reduced the incidence of CI-AKI but without an impact on the incidence of AKI warranting dialysis. Large clinical trials examining the potential beneficial effects of high dose statins are warranted.

Incidence of CI-AKI with statins and placebo